Meta-analysis on effect of esketamine in combination with remazolam besylate for patients taking endoscopic retrograde cholangiopancreatography
Objective To systematically review the effect of esketamine in combination with remazolam besylate for patients taking endoscopic retrograde cholangiopancreatography(ERCP).Methods The randomized controlled trials(RCTs)on esketamine and remimazolam besylate for patients taking ERCP published at CNKI,VIP,Wanfang,PubMed,Web of Science,Embase,and the Cochrance Library from their establishment to March 2023 were searched.The experimental group was anesthetized with the combination of ketamine and remifentanil besylate for ERCP,while the control group with other intravenous anesthetics.Two unrelated researchers carefully screened the literatures based on the inclusion and exclusion criteria,and conducted statistical analysis using the Review Manager 5.4 software.Results Six RCTs were included,with a total of 532 patients.Compared with other anesthesia drug regimens,the esketamine combined with remazolam besylate group had lower probabilities of hypotension and respiratory depression(RR=0.29,95％CI 0.17～0.50;RR=0.18,95％CI 0.08～0.38).Conclusion The combined use of ketamine and remazolam besylate for patients taking ERCP can significantly reduce the probability of adverse events,and is a more stable and safer anesthesia method.
国家科技期刊平台
NSTL
万方数据
